Inhibitor Therapeutics, Inc.
INTI
$0.08
$0.0110.26%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 53.52% | -1.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 77.43% | 6.52% | |||
| Operating Income | -77.43% | -6.52% | |||
| Income Before Tax | -81.89% | -7.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -81.89% | -7.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -81.89% | -7.93% | |||
| EBIT | -77.43% | -6.52% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -82.93% | -7.89% | |||
| Normalized Basic EPS | -80.77% | -8.33% | |||
| EPS Diluted | -82.93% | -7.89% | |||
| Normalized Diluted EPS | -80.77% | -8.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||